Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-02
2006-05-02
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S122000, C546S123000
Reexamination Certificate
active
07037922
ABSTRACT:
Disclosed are compounds of formula (I) or pharmaceutically acceptable non-toxic salts or pharmaceutically acceptable solvates thereof wherein: (II) represents (a), (b), (c) or (d) and W, X, Y, A, B, C, D, E are variables as described herein. These compounds are highly selective agonists or antagonists at NK3 receptors or prodrugs thereof. The novel tachykinin NK-3 receptor antagonists contained in this invention have potential utility in the treatment of a broad array of disorders and diseases of the central nervous system (CNS) and periphery in mammals in which activation of NK-3 receptors is of importance.
REFERENCES:
patent: 5811553 (1998-09-01), Farina et al.
patent: 6277862 (2001-08-01), Giardina et al.
patent: 6355654 (2002-03-01), Giardina et al.
patent: 6432977 (2002-08-01), Giardina et al.
patent: 6608083 (2003-08-01), Farina et al.
patent: 6613770 (2003-09-01), Farina et al.
patent: 6743804 (2004-06-01), Giardina et al.
patent: 6780875 (2004-08-01), Farina et al.
patent: 829894 (1952-01-01), None
patent: WO 97/19926 (1997-06-01), None
patent: 00/31037 (2000-06-01), None
patent: 02/38547 (2002-05-01), None
patent: 02/38548 (2002-05-01), None
patent: 02/43734 (2002-06-01), None
patent: 02/44154 (2002-06-01), None
Gao et al, Current Medicinal Chemistry, 1999, 6: 375-388.
Giardina, et al., (1999)IL FARMACO,54:364-374.
Hutchison Alan
Maynard George
Yuan Jun
Davis Zinna Northington
McDonnell Boehnen & Hulbert & Berghoff LLP
Neurogen Corporation
LandOfFree
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3596346